Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

UCB Launches High Dose Bimekizumab in the US

Jan 16, 2025

On 16 January 2025, UCB announced that it has launched in the US a high dose presentation of Bimzelx® (bimekizumab-bkzx) in a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of Bimzelx®.  This is in addition to the currently available 1 mL (160 mg) device administration options and follows FDA approval of the presentation in October 2024.

UCB’s Bimzelx® has received several FDA approvals for new indications in recent months, including for moderate to severe hidradenitis suppurativa (November 2024), and for active psoriatic arthritis, active non-radiographic axial spondyloarthritis and active ankylosing spondylitis (September 2024).

In May 2025, Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) will consider UCB’s application to PBS-list Bimzelx® for moderate to severe hidradenitis suppurativa.